Tel.:
+34 91 736 2385
LOCAL TIME
Contact:
Katarina Gluic
Hours:
Mon-Thu 8:30-17:00 Fri 8:30-15:00
13:04
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
52nd ERA-EDTA Congress
28-31 May 2015 London
About us
FAQs
Help Line
Personal Area
Homepage
Discussion forum -
52nd ERA-EDTA Congress
Topic -
M1) Renal transplantation. Experimental, immune-tolerance of allogenic and xenogenic transplants.
If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
Thread / Poster
Author
Replies
Last reply
RISK FACTORS AND THEIR RELATIVE STRENGTHS FOR NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT)
alshamsi shaikha ali
1
5/18/2015 10:58:00 AM
RATE OF GFR FALL OVER TIME, 24H AMBULATORY BP MONITORING AND OFFICE BP IN TRANSPLANT PATIENTS.
Francesca Mallamaci
1
5/18/2015 9:39:00 AM
DYSREGULATED TH17 CELL IS ASSOCIATED WITH CHRONIC CALCINEURIN INHIBITOR TOXICITY IN RENAL ALLOGRAFT RECIPIENTS.
Brijesh Yadav
1
5/18/2015 8:52:00 AM
INDOLEAMINE 2,3-DIOXYGENASE (IDO) UPREGULATION IS AN INDEPENDENT PREDICTOR OF SUSCEPTIBILITY TO INFECTIONS IN KIDNEY TRANSPLANT PATIENTS
Licia Peruzzi
1
5/17/2015 4:35:00 PM
INCREASD INTRAGRAFT MRNA TRANSCRIPT OF GRANZYME-B IS ASSOCIATED WITH CHRONIC TRANSPLANT GLOMERULOPATHY
Narayan Prasad
1
5/13/2015 12:31:00 PM
RENOPROTECTIVE EFFECTS OF EPIGALLOCATECHIN GALLATE AND CANDESARTAN ON STREPTOZOTOCIN INDUCED DIABETIC NEPHROPATHY IN MICE
JONG HOON CHUNG
1
5/4/2015 2:33:00 AM
Most viewed poster for this congress
Poster:
625
Visits:
3858
Title:
IS 4 CITRATE AN EFFECTIVE TOOL AS A CATHETER LOCKING SOLUTION?
Authors:
Joao Fazendeiro Matos ,
Centre:
Fresenius Medical Care | NephroCare Portugal
Poster most viewed in this topic
Poster:
834
Visits:
96
Title:
RISK FACTORS AND THEIR RELATIVE STRENGTHS FOR NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT)
Authors:
alshamsi Shaikha ali ,
Centre:
king abdulaziz medical city, Riyadh
About us
Terms and Conditions
Special Access
Commercial Web Access
Follow us on: